535 related articles for article (PubMed ID: 34350585)
21. Will new agents impact survival in AML?
Rowe JM
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101094. PubMed ID: 31779986
[TBL] [Abstract][Full Text] [Related]
22. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
[TBL] [Abstract][Full Text] [Related]
23. Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.
Sami SA; Darwish NHE; Barile ANM; Mousa SA
Curr Treat Options Oncol; 2020 Jan; 21(1):3. PubMed ID: 31933183
[TBL] [Abstract][Full Text] [Related]
24. Novel Therapies in Acute Myeloid Leukemia.
Mukherjee S; Sekeres MA
Semin Oncol Nurs; 2019 Dec; 35(6):150955. PubMed ID: 31759818
[TBL] [Abstract][Full Text] [Related]
25. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
DiNardo CD; Stein EM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
[TBL] [Abstract][Full Text] [Related]
26. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
27. New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise.
Bohl SR; Bullinger L; Rücker FG
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018543
[TBL] [Abstract][Full Text] [Related]
28. An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.
Venugopal S; Xie Z; Zeidan AM
Expert Rev Hematol; 2023 Feb; 16(2):109-119. PubMed ID: 36718500
[TBL] [Abstract][Full Text] [Related]
29. New and emerging therapies for acute myeloid leukaemia.
Davis JR; Benjamin DJ; Jonas BA
J Investig Med; 2018 Dec; 66(8):1088-1095. PubMed ID: 30127098
[TBL] [Abstract][Full Text] [Related]
30. The Time Has Come for Targeted Therapies for AML: Lights and Shadows.
Fiorentini A; Capelli D; Saraceni F; Menotti D; Poloni A; Olivieri A
Oncol Ther; 2020 Jun; 8(1):13-32. PubMed ID: 32700072
[TBL] [Abstract][Full Text] [Related]
31. Updates on DNA methylation modifiers in acute myeloid leukemia.
Contieri B; Duarte BKL; Lazarini M
Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
[TBL] [Abstract][Full Text] [Related]
32. Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy.
Marchetti M; Albertin L; Limberti G; Canicattì M
Expert Opin Pharmacother; 2022 Feb; 23(2):263-272. PubMed ID: 34886738
[TBL] [Abstract][Full Text] [Related]
33. Progress and predictions: AML in 2018.
Rowe JM
Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
[TBL] [Abstract][Full Text] [Related]
34. Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
Loke J; Metzner M; Boucher R; Jackson A; Hopkins L; Pavlu J; Tholouli E; Drummond M; Peniket A; Bishop R; Fox S; Vyas P; Craddock C
Br J Haematol; 2022 Jan; 196(2):368-373. PubMed ID: 34490623
[TBL] [Abstract][Full Text] [Related]
35. Advancements and Challenges in the Treatment of AML.
Abaza Y; McMahon C; Garcia JS
Am Soc Clin Oncol Educ Book; 2024 Apr; 44(3):e438662. PubMed ID: 38662975
[TBL] [Abstract][Full Text] [Related]
36. IDH Inhibitors in AML-Promise and Pitfalls.
McMurry H; Fletcher L; Traer E
Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107
[TBL] [Abstract][Full Text] [Related]
37. FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
Hogan FL; Williams V; Knapper S
Curr Cancer Drug Targets; 2020; 20(7):513-531. PubMed ID: 32418523
[TBL] [Abstract][Full Text] [Related]
38. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
Yamauchi T
Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
[TBL] [Abstract][Full Text] [Related]
39. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
Megías-Vericat JE; Solana-Altabella A; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
Ann Hematol; 2020 Sep; 99(9):1989-2007. PubMed ID: 32683457
[TBL] [Abstract][Full Text] [Related]
40. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]